Goldman Myla Lai - 16 Sep 2021 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Director
Signature
/s/ Myla Lai-Goldman, by Brian McKelligon, as Attorney-in-Fact
Issuer symbol
AKYA
Transactions as of
16 Sep 2021
Transactions value $
$0
Form type
4
Date filed
20 Sep 2021, 20:51
Next filing
26 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Stock Option (Right to Buy Award $0 +39K $0.00 39K 16 Sep 2021 Common Stock 39K $18.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to the reporting person's continuous service through the vesting date, the options shall vest in three (3) equal installments beginning on September 16, 2022 and annually thereafter until fully vested.